| 1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2. |
歐陽飛, 石磊. 1990-2021年中國及全球女性乳腺癌疾病負擔分析和未來趨勢預測[J]. 中國循證醫學雜志, 2025, 25(5): 497-503.
|
| 3. |
Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis[J]. Ann Oncol, 2018, 29(7): 1497-1508.
|
| 4. |
邵笛, 余天劍, 邵志敏. 三陰性乳腺癌精準治療研究進展[J]. 中國普通外科雜志, 2023, 32(11): 1629-1638.
|
| 5. |
Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer[J]. Brit Med J, 2023, 381: e071674.
|
| 6. |
Mukhtar RA, Chau H, Woriax H, et al. Breast conservation surgery and mastectomy have similar locoregional recurrence after neoadjuvant chemotherapy: results from 1 462 patients on the prospective, randomized I-SPY2 trial[J]. Ann Surg, 2023, 278(3): 320-327.
|
| 7. |
Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis[J]. Brit Med J, 2021: e066381.
|
| 8. |
Squifflet P, Saad ED, Loibl S, et al. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy[J]. J Clin Oncol, 2023, 41(16): 2988-2997.
|
| 9. |
Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages Ⅰ to Ⅲ colorectal cancer[J]. JAMA Oncol, 2019, 5(8): 1124-1131.
|
| 10. |
Panet F, Papakonstantinou A, Borrell M, et al. Use of ctDNA in early breast cancer: analytical validity and clinical potential[J]. NPJ Breast Cancer, 2024, 10: 50.
|
| 11. |
Cohen SA, Liu MC, Aleshin A. Practical recommendations for using ctDNA in clinical decision making[J]. Nature, 2023, 619(7969): 259-268.
|
| 12. |
Herberts C, Wyatt AW. Technical and biological constraints on ctDNA-based genotyping[J]. Trends Cancer, 2021, 7(11): 995-1009.
|
| 13. |
Bonanno L, Dal Maso A, Pavan A, et al. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg[J]. Br J Cancer, 2022, 127(3): 383-393.
|
| 14. |
Duffy MJ, Crown J. Use of circulating tumour DNA (ctDNA) for measurement of therapy predictive biomarkers in patients with cancer[J]. J Pers Med, 2022, 12(1): 99.
|
| 15. |
Duffy MJ. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction[J]. Tumor Biol, 2024, 46(s1): S283-S295.
|
| 16. |
Alba-Bernal A, Lavado-Valenzuela R, Domínguez-Recio ME, et al. Challenges and achievements of liquid biopsy technologies employed in early breast cancer[J]. Ebiomedicine, 2020, 62: 103100.
|
| 17. |
Moding EJ, Nabet BY, Alizadeh AA, et al. Detecting liquid remnants of solid tumors: circulating tumor dna minimal residual disease[J]. Cancer Discov, 2021, 11(12): 2968-2986.
|
| 18. |
Chi Y, Su M, Zhou D, et al. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: a prospective study[J]. Elife, 2023, 12: e90198.
|
| 19. |
Coakley M, Villacampa G, Sritharan P, et al. Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer[J]. Clin Cancer Res, 2024, 30(4): 895-903.
|
| 20. |
Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system[J]. J Clin Oncol, 2007, 25(15): 2127-2132.
|
| 21. |
Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors[J]. Ann Intern Med, 2013, 158(4): 280-286.
|
| 22. |
Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies[J]. Brit Med J, 2019, 364: k4597.
|
| 23. |
Ortolan E, Appierto V, Silvestri M, et al. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy[J]. ESMO Open, 2021, 6(2): 100086.
|
| 24. |
Lin PH, Wang MY, Lo C, et al. Circulating tumor DNA as a predictive marker of recurrence for patients with stage Ⅱ-Ⅲ breast cancer treated with neoadjuvant therapy[J]. Front Oncol, 2021, 11.
|
| 25. |
Stecklein SR, Kimler BF, Yoder R, et al. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease[J]. NPJ Breast Cancer, 2023, 9(1): 10.
|
| 26. |
Zaikova E, Cheng BYC, Cerda V, et al. Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment[J]. NPJ Breast Cancer, 2024, 10(1): 1-21.
|
| 27. |
Cavallone L, Aguilar-Mahecha A, Lafleur J, et al. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer[J]. Sci Rep, 2020, 10(1): 1-14.
|
| 28. |
Chen YH, Hancock BA, Solzak JP, et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy[J]. NPJ Breast Cancer, 2017, 3(1): 1-13.
|
| 29. |
Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer preplanned secondary analysis of the BRE12-158 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1410-1415.
|
| 30. |
Magbanua MJM, Brown Swigart L, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy[J]. Cancer Cell, 2023, 41(6): 1091-1102.
|
| 31. |
Mittendorf EA, Zhang H, Barrios C H, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100.
|
| 32. |
Yee D, DeMichele AM, Yau C, et al. Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer[J]. JAMA Oncol, 2020, 6(9): 1-9.
|
| 33. |
Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer[J]. JAMA Oncol, 2019, 5(10): 1473-1478.
|
| 34. |
Parsons HA, Blewett T, Chu X, et al. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030[J]. Ann Oncol, 2023, 34(10): 899-906.
|
| 35. |
Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival[J]. Ann Oncol, 2021, 32(2): 229-239.
|